Tables of Rules

NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

Nucleoside and Nucleotide reverse transcriptase inhibitors Protease inhibitors

Non-Nucleoside reverse transcriptase inhibitors Fusion inhibitors

HIV - 2 Integrase inhibitors


  Mutations associated with resistance Mutations associated with « possible resistance »
EFV
L100I
K101E
K103H/N/S/T [1]
V106M [2]
Y181C/I
Y188C/L
G190A/C/E/Q/S/T/V
P225H
M230L

NVP
A98S (for HIV-1 subtype C only) [3]
L100I
K101E
K103H/N/S/T [1]
V106A/M [2]
Y181C/I
Y188C/H/L
G190A/C/E/Q/S/T/V
M230L

ETR

At least 4 among: V90I, A98G, L100I, K101E/H/I/P/R, V106I, V179D/F/I/L/M/T, Y181C/I, G190A/S,M230L [4,7,8,9, 10, 11]
Y181V [5, 6]
Y181C+H221Y [7]
3 mutations among: V90I, A98G, L100I, K101E/H/I/P/R, V106I, V179D/F/I/L/M/T, Y181C/I, G190A/S,M230L [4,7,8,9, 10, 11]
E138A/G/K/Q/R [5, 6, 7, 8]

EFV: efavirenz, NVP: nevirapine, ETR (TMC125): etravirine
Mutations associated with antiretroviral regimen but with uncertain signification: K101H/N/P/Q

References